Denise is currently the Chief Business Officer and Member of the Management Board at Affimed. She has built a strong reputation for developing high-impact strategies, structures, teams, and alliances that have fueled business results, impact to stock value, and market expansion across multiple therapeutic areas.
In her current role, within the last 2 ½ years Denise led the capture of $156M in cash via upfront payments thru business development and advanced the company’s position as a pioneer in immuno-oncology. She secured strategic collaborations with Genentech and Roivant as well as clinical and pre-clinical collaborations with Merck, Roche, NKMax, and Artiva.
Concurrently, as the President of Affimed US, Denise built the US organization to operationalize and scale the business. She has held various leadership roles at Pfizer, Wyeth Pharmaceuticals as well.
Denise holds a Bachelor of Science degree from Virginia Polytechnic Institute and State University.
In her current role, within the last 2 ½ years Denise led the capture of $156M in cash via upfront payments thru business development and advanced the company’s position as a pioneer in immuno-oncology. She secured strategic collaborations with Genentech and Roivant as well as clinical and pre-clinical collaborations with Merck, Roche, NKMax, and Artiva.
Concurrently, as the President of Affimed US, Denise built the US organization to operationalize and scale the business. She has held various leadership roles at Pfizer, Wyeth Pharmaceuticals as well.
Denise holds a Bachelor of Science degree from Virginia Polytechnic Institute and State University.
Activity